TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35818888
Drug: Medication management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication management strategies
Study: 35819130
Drug: Weekly digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly digital follow-up of lung cancer patients
Study: 35819130
Drug: Weekly digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly digital follow-up of lung cancer patients (pilot study)
Study: 35819446
Drug: miR-146b-5p mimic
Normalized name: Pyridoxal-5P
DrugBank: Pyridoxal phosphate (DB00114)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: miR-146b-5p mimic administration to NSG mice engrafted with CLL cells
Study: 35819446
Drug: Downregulation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Downregulation of miR-146b-5p with specific miRNA inhibitors in vitro
Study: 35820054
Drug: Opal patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opal patient portal intervention for distance monitoring of self-isolating patients with COVID-19, involving daily self-assessment of symptoms, vital signs, and mental health monitored by a nurse, with teleconsultations as needed.
Study: 35820718
Drug: Umbilical cord
Normalized name: Sus Scrofa Umbilical Cord
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umbilical cord mesenchymal stromal cells (UC MSCs) infusion (1×10^6 cells)
Study: 35820718
Drug: Umbilical cord
Normalized name: Sus Scrofa Umbilical Cord
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umbilical cord mesenchymal stromal cells (UC MSCs) infusion
Study: 35820889
Drug: APG-2449 in
Normalized name: APGA
DrugBank: Aminopterin (DB08878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APG-2449 in combination with paclitaxel
Study: 35821349
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (GnRH-ant) protocol
Study: 35821349
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRH-a) protocol
Study: 35821380
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (IVT-AFL) treatment intervals of < 8 weeks
Study: 35821380
Drug: Non-injection-intensive patients
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-injection-intensive patients
Study: 35821806
Drug: Uthever (NMN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uthever (NMN Supplement)
Study: 35821844
Drug: Glycine and
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycine and N-Acetylcysteine supplementation (GlyNAC) at low dose (2.4 g/day) for 2 weeks
Study: 35821844
Drug: Glycine and
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycine and N-Acetylcysteine supplementation (GlyNAC) at medium dose (4.8 g/day) for 2 weeks
Study: 35821844
Drug: Glycine and
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycine and N-Acetylcysteine supplementation (GlyNAC) at high dose (7.2 g/day) for 2 weeks
Study: 35822945
Drug: Average PrEP
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average PrEP dosing
Study: 35829780
Drug: Rituximab combined
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab combined with intensive chemotherapy (group R1)
Study: 35829780
Drug: Rituximab combined
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab combined with intensive chemotherapy (group R2)
Study: 35829780
Drug: Rituximab combined
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab combined with intensive chemotherapy (group R3)
Study: 35829780
Drug: Rituximab combined
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab combined with intensive chemotherapy (group R4)
Study: 35830707
Drug: Structured approach
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured approach including daily assessment of readiness to extubate
Study: 35830841
Drug: Lurbinectedin at
Normalized name: lurbinectedin
DrugBank: Lurbinectedin (DB12674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lurbinectedin at 3.2 mg/m
Study: 35830931
Drug: Arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Arsenic trioxide (ATO) at 1 mg/kg/day, with 11 infusions per cycle of 28 days at a dose of 0.15 mg/kg per infusion.
Study: 35830931
Drug: Arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Arsenic trioxide (ATO) treatment
Study: 35831040
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment in UAP patients
Study: 35831783
Drug: MRd (Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRd (Medication Reconciliation at discharge)
Study: 35832045
Drug: Rehabilitation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation of masticatory function with fixed implant-supported dentures and nutrition education
Study: 35832177
Drug: Ozanimod 0.92
Normalized name: ozanimod 0.92 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanimod 0.92 mg/day after initial dose escalation for up to 60 months
Study: 35832177
Drug: Ozanimod 0.92
Normalized name: ozanimod 0.92 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanimod 0.92 mg/day
Study: 35832286
Drug: Elevated hsCRP
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated hsCRP levels (>3 mg/l) in FM patients
Study: 35832447
Drug: Camrelizumab 200
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab 200 mg intravenously every 2 weeks plus apatinib 250 mg orally once daily
Study: 35834242
Drug: High baseline
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High baseline remnant-C (≥31 mg/dL)
Study: 35834242
Drug: High baseline
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High baseline remnant-C in LDL-C subgroup (>100 mg/dL)
Study: 35834242
Drug: High baseline
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High baseline remnant-C in LDL-C subgroup (≤100 mg/dL)
Study: 35834598
Drug: Neoadjuvant mFOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant mFOLFOXIRI chemotherapy
Study: 35835137
Drug: Zandelisib 60
Normalized name: Zandelisib
DrugBank: Zandelisib (DB18245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zandelisib 60 mg once daily (intermittent dosing)
Study: 35835137
Drug: Zandelisib 120
Normalized name: Zandelisib
DrugBank: Zandelisib (DB18245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zandelisib 120 mg once daily (intermittent dosing)
Study: 35835137
Drug: Zandelisib 180
Normalized name: Zandelisib
DrugBank: Zandelisib (DB18245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zandelisib 180 mg once daily (intermittent dosing)
Study: 35835137
Drug: Zandelisib (intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zandelisib (intermittent dosing)
Study: 35835137
Drug: Zandelisib (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zandelisib (continuous dosing)
Study: 35835137
Drug: Zandelisib (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zandelisib (both dosing schedules)
Study: 35835491
Drug: SCAI staging
Normalized name: fluorexon stain
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCAI staging system parameters (hypotension, hypoperfusion, treatment intensity)
Study: 35835611
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg Q3W for 35 cycles
Study: 35835738
Drug: Antibody-dependent phagocytosis
Normalized name: Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody-dependent phagocytosis of ring-infected erythrocytes
Study: 35835738
Drug: Antibody-dependent phagocytosis
Normalized name: Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody-dependent phagocytosis of uninfected erythrocytes
Study: 35837200
Drug: Dose-escalated proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalated proton therapy with elective nodal irradiation (40.5 GyRBE in 18 fractions followed by 22.5 GyRBE boost); Oral capecitabine (1,000 mg twice daily) during treatment
Study: 35837200
Drug: Dose-escalated proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalated proton therapy with elective nodal irradiation
Study: 35837409
Drug: Butantan-DV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butantan-DV vaccine
Study: 35838207
Drug: Antitumor treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antitumor treatment (surgery, radiotherapy, chemotherapy)
Study: 35838207
Drug: Antiepileptic drug
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drug (AED) treatment (levetiracetam)
Study: 35838207
Drug: Benzodiazepines via
Normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepines via nonoral administration routes
Study: 35838993
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg 1% propofol (group P: n = 30)
Study: 35838993
Drug: No propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No propofol administration (group C: n = 83)
Study: 35839426
Drug: Postconsolidation immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postconsolidation immunotherapy including dinutuximab, granulocyte-macrophage colony-stimulating factor, and interleukin-2
Study: 35840573
Drug: Amcenestrant 20-600
Normalized name: Amcenestrant
DrugBank: SAR-439459 (DB17864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amcenestrant 20-600 mg QD
Study: 35840912
Drug: Short-course preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course preoperative radiotherapy (5 Gy × 5 days) and pembrolizumab (4 injections starting on the same day and on weeks 4, 7, and 10)
Study: 35841307
Drug: Local therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local therapy (initial primary surgery in 7 cases)
Study: 35841307
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy (5 patients)
Study: 35842229
Drug: 1+ incident
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1+ incident HPV of any, oncogenic, non-oncogenic and vaccine-preventable types
Study: 35842567
Drug: Trilaciclib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trilaciclib (200 or 240 mg/m)
Study: 35842567
Drug: Trilaciclib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trilaciclib (200 or 240 mg/m) with rifampin
Study: 35842567
Drug: Trilaciclib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trilaciclib (200 or 240 mg/m) with itraconazole
Study: 35843046
Drug: Balanced solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced solutions (Plasma Lye 148)
Study: 35843046
Drug: Balanced solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced solutions (Plasma Lye 148) in traumatic brain injury patients
Study: 35843546
Drug: AB680 (CD73
Approvals — FDA: no, EMA: no, PMDA: no
Description: AB680 (CD73 inhibitor)
Study: 35843546
Drug: palbociclib (CDK4/6
Approvals — FDA: no, EMA: no, PMDA: no
Description: palbociclib (CDK4/6 inhibitor)
Study: 35843546
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of AB680 and palbociclib
Study: 35843739
Drug: Sapanisertib 3
Normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sapanisertib 3 or 4 mg, Serabelisib 200 mg on days 2-4, 9-11, 16-18 and 23-25 with Paclitaxel 80 mg/m2 on days 1, 8 and 15 every 28 days
Study: 35844014
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow concentrate (BMC) injections
Study: 35844168
Drug: OROS-MPH (osmotic-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS-MPH (osmotic-release oral system methylphenidate)
Study: 35844168
Drug: Omega-3 with
Normalized name: Omega-3 With CoQ10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 with risperidone and usual anti-seizure medication (ASM)
Study: 35844773
Drug: Topical ENERGI-F703
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ENERGI-F703 gel applied twice daily for 12 weeks or until complete ulcer closure
Study: 35844773
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle gel applied twice daily for 12 weeks or until complete ulcer closure
Study: 35845461
Drug: Socio-demographic, clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Socio-demographic, clinical and biological assessments including blood and hair cortisol levels, plasma pro- and mature BDNF isoforms proportion
Study: 35845530
Drug: Neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment for LARC
Study: 35845797
Drug: Multispecies synbiotic
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multispecies synbiotic supplement (once daily for 12 weeks)
Study: 35846031
Drug: Avadomide (CC-122)
Normalized name: Avadomide
DrugBank: Avadomide (DB14857)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avadomide (CC-122) 3 mg/day 5 days on/2 days off plus rituximab 375 mg/m2
Study: 35846096
Drug: Oral selinexor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral selinexor plus low-dose dexamethasone (Sel-dex)
Study: 35846096
Drug: Other available
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other available therapies (control group)
Study: 38415370
Drug: Physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice of treatment (PCT)
Study: 35846221
Drug: CC-122 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-122 plus rituximab
Study: 35846221
Drug: CC-223 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-223 and CC-292 combinations
Study: 35846226
Drug: Lebrikizumab 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab 37.5 mg
Study: 35846272
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of hyperaldosteronism
Study: 35847877
Drug: Gallium68-fibroblast-activation protein
Normalized name: Activated protein C
DrugBank: Drotrecogin alfa (DB00055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallium68-fibroblast-activation protein inhibitor
Study: 35848614
Drug: ISIKOK-19 T-cell
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIKOK-19 T-cell therapy
Study: 35848990
Drug: 1.25% pilocarpine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25% pilocarpine ophthalmic solution eye drops
Study: 35850782
Drug: XR-NTX treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: XR-NTX treatment
Study: 35852004
Drug: Durvalumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab monotherapy (Arm D)
Study: 35852004
Drug: Durvalumab in
Normalized name: durvalumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab in combination with lenalidomide ± rituximab (Arm A)
Study: 35852004
Drug: Durvalumab in
Normalized name: durvalumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab in combination with ibrutinib (Arm B)
Study: 35852004
Drug: Durvalumab in
Normalized name: durvalumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab in combination with rituximab ± bendamustine (Arm C)
Study: 35852004
Drug: Durvalumab (monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (monotherapy or combination)
Study: 35852094
Drug: transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: transcranial direct current stimulation (tDCS) at 2 mA for 30 minutes daily for 4 months
Study: 35852619
Drug: Modified DEP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified DEP regimen as induction therapy
Study: 35852839
Drug: AG-920, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG-920, a topical ocular anesthetic
Study: 35853530
Drug: Omnipod® 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omnipod® 5 Automated Insulin Delivery (AID) System
Study: 35853681
Drug: Testing for
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testing for T790M mutation after progression on 1L treatment
Study: 35853681
Drug: Second-line (2L)
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line (2L) treatment with osimertinib
Study: 35853994
Drug: ERY974 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERY974 at a starting dose of 3.0 ng/kg
Study: 35853994
Drug: ERY974 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERY974 at 0.1 μg/kg
Study: 35854137
Drug: Botulinum neurotoxin
Normalized name: Botulinum neurotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum neurotoxin (BoNT) injection
Study: 35854321
Drug: ATLAS 2030
Normalized name: LACTIC ACID 0.58 g in 100 g TOPICAL LIQUID [Atlas Prep Activator]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATLAS 2030 gait exoskeleton, used for nine sessions bi-weekly of 60 min each.
Study: 35854324
Drug: Mental distress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mental distress during TB investigation and treatment
Study: 35854392
Drug: Unified Internet-delivered
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unified Internet-delivered exposure treatment
Study: 35857405
Drug: Anlotinib (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib (12 mg/day, orally, 2 weeks on and 1 week off, every 3 weeks) plus Toripalimab (240 mg, intravenously over 60 minutes, once every 2 weeks)
Study: 35857579
Drug: Intradermal delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal delivery of tremelimumab (2 to 20 mg)
Study: 35858586
Drug: MVA-MERS-S vaccine
Normalized name: MVA-SARS-2-S
DrugBank: MVA-SARS-2-S (DB16432)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-MERS-S vaccine (modified vaccinia virus Ankara-based vaccine) administered on days 0 and 28 with a late booster vaccination at 12 ± 4 months.
Study: 35858849
Drug: Selective Internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective Internal Radiation Therapy (SIRT) using TheraSpheres
Study: 35860245
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard therapy with dexamethasone)
Study: 35860581
Drug: Three-dimensional conformal
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dimensional conformal radiation therapy (3D-CRT)
Study: 35861072
Drug: Prehospital administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prehospital administration of thawed plasma (TP)
Study: 35861296
Drug: Higher-dose rifampicin
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher-dose rifampicin (35 mg/kg)
Study: 35861370
Drug: Acalabrutinib 100
Normalized name: acalabrutinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib 100 mg twice daily until disease progression or unacceptable toxicity
Study: 35861706
Drug: Online support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online support group participation (3 times weekly for 6 weeks)
Study: 35862034
Drug: Elo-KRd (elotuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elo-KRd (elotuzumab and weekly carfilzomib, lenalidomide, and dexamethasone)
Study: 35862035
Drug: Icotinib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icotinib (125 mg 3 times daily) until disease progression, death, or treatment discontinuation.
Study: 35862184
Drug: mHealth app
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth app (BMT4me) designed to promote adherence to immunosuppressant medication and track symptoms
Study: 35862185
Drug: Remote monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remote monitoring solutions implementation
Study: 35862743
Drug: Dihydroartemisinin-piperaquine (DHA-PQP)
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (DHA-PQP) 2.1/17.1 mg/kg, administered monthly for 3 consecutive months.
Study: 35863672
Drug: Nab-paclitaxel (level
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nab-paclitaxel (level 2 dose at 75 mg/m²), capecitabine, and radiation therapy after induction chemotherapy
Study: 35864209
Drug: 150 mm
Normalized name: Tenscare Electrodes Joint 150 mm Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mm Drug-Coated Balloon (DCB)
Study: 35865463
Drug: Pharmacogenetic (PGx)
Normalized name: PGX
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacogenetic (PGx) testing prior to chemotherapy initiation
Study: 35865476
Drug: Early enteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early enteral nutrition (250 ml/12 h, increased daily to 1000 ml/12 h if tolerated)
Study: 35865476
Drug: Oral nutrition
Normalized name: BAGS/TUBES/SUPPLIES FOR ORAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutrition
Study: 35867239
Drug: Transcrestal sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcrestal sinus floor elevation with injectable xenograft in gel form
Study: 35867385
Drug: Radioiodine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine treatment (1.1 GBq and 3.7 GBq groups)
Study: 35867399
Drug: SADL-eM (Spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: SADL-eM (Spinal Cord Injury Activities of Daily Living Education Manual)
Study: 35867947
Drug: Enzalutamide (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzalutamide (160 mg orally once daily)